The NeoLAB Solid Tumor Liquid Biopsy is a next-gen sequencing assay designed to detect mutations in cell-free circulating tumor DNA of patients with solid tumors (pan-cancer). Analytic validation demonstrated accuracy of 98.0%, sensitivity of 95.1%, and specificity of 98.8%. The NeoLAB® Solid Tumor Liquid Biopsy includes targets significant to a wide variety of solid tumors including colorectal, pancreas, prostate, melanoma, head & neck, bladder, thyroid, kidney, ovarian, liver, thyroid, breast, and lung. Tissue testing is recommended over plasma testing when possible.
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Thyroid Gland Carcinoma
AKT1 (V-akt murine thymoma viral oncogene homolog 1), ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), AR (Androgen receptor), ARAF (A-Raf Proto-Oncogene), BRAF (B-raf proto-oncogene)
See More ...
Next-Generation Sequencing (NGS)